文献速递肿瘤 PET/CT

晚期黑色素瘤患者基线与治疗中18F-FLT摄取生物分布变异性:简报

Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication.
PubMed 文献 · Clin Nucl Med · 2024-05-14

这项前瞻性研究评估了18例BRAF阳性不可切除IIIc期或IV期黑色素瘤患者在接受BRAF/MEK抑制剂治疗前(BL)和治疗中(D14)的18F-FLT PET生物分布。基线患者间18F-FLT摄取的变异系数在17.5%至21.5%之间;治疗期间肝脏摄取增高(SUV meanBL=4.86±0.98,SUV meanD14=6.31±1.36,P<0.001),骨髓摄取降低(SUV meanBL=7.67±1.65,SUV meanD14=6.78±1.19,P<0.025),两项变化均与基线代谢肿瘤体积或肿瘤反应无关。结论认为基线与治疗中肝脏和骨髓摄取均可作为正常组织参考,但接受BRAF/MEK抑制剂治疗时纵向反应研究中18F-FLT生物分布显著变化。

要点

  • 基线患者间18F-FLT摄取的变异系数为17.5%至21.5%。
  • 治疗期间肝脏SUV mean由4.86±0.98升至6.31±1.36(P<0.001)。
  • 治疗期间骨髓SUV mean由7.67±1.65降至6.78±1.19(P<0.025)。

核心结论

  • 评估18F-FLT PET时,基线与治疗中肝脏和骨髓摄取均可作为正常组织参考,但接受BRAF/MEK抑制剂治疗时纵向反应研究中18F-FLT生物分布显著变化。

研究设计与样本

  • 前瞻性研究纳入18例BRAF阳性不可切除IIIc期或IV期黑色素瘤患者,在BRAF/MEK抑制剂治疗前(BL)和治疗中(D14)行18F-FLT PET/CT。
  • 对肝脏、骨髓、血液和肌肉的18F-FLT累积进行定量。

主要发现

  • 基线患者间18F-FLT摄取的变异系数在17.5%至21.5%之间。
  • 治疗期间肝脏摄取增高(SUV meanBL=4.86±0.98,SUV meanD14=6.31±1.36,P<0.001)。
  • 治疗期间骨髓摄取降低(SUV meanBL=7.67±1.65,SUV meanD14=6.78±1.19,P<0.025)。
  • 肝脏和骨髓摄取的两项变化均与基线代谢肿瘤体积或肿瘤反应无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This prospective study evaluates the biodistribution of 18 F-FLT PET in patients with advanced melanoma before and after treatment with BRAF/MEK inhibitors. PATIENTS AND METHODS: Eighteen BRAF-positive unresectable stage IIIc or IV melanoma patients referred for 18 F-FLT PET/CT before (BL) and during (D14) BRAF/MEK inhibition were included. 18 F-FLT accumulation in the liver, bone marrow, blood, and muscle was quantified. RESULTS: Baseline interpatient 18 F-FLT uptake had a coefficient-of-variation between 17.5% and 21.5%. During treatment, liver uptake increased (SUV meanBL = 4.86 ± 0.98, SUV meanD14 = 6.31 ± 1.36, P < 0.001) and bone marrow uptake decreased (SUV meanBL = 7.67 ± 1.65, SUV meanD14 = 6.78 ± 1.19, P < 0.025). Both changes were unrelated to baseline metabolic tumor volume or tumor response. CONCLUSIONS: To assess 18 F-FLT PET, both liver and bone marrow uptake may be used as normal tissue references at baseline, but 18 F-FLT biodistribution significantly changes in longitudinal response studies when treated with BRAF/MEK inhibitors.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. van der Hiel B, Aalbersberg EA, van den Eertwegh AJM, et al. Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication. Clin Nucl Med. 2024. PMID: 38768063. doi:10.1097/RLU.0000000000005281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。